A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
Completed · Phase 1 · NCT06698926
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $31,380
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 110
About the trial
- Sponsor
- AbbVie (with Calico Life Sciences LLC)
- Tested
- ABBV-CLS-616 (drug), Placebo (drug), Itraconazole (drug)
- Dates
- Started 2024-11-11; completion 2026-01-09
- Results posted
- Not yet
This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
From ClinicalTrials.gov, last updated 2026-01-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $31,380 in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $31,380
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.